Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Acorda Therapeutics Inc.
WARNING LETTER
•Acorda Therapeutics Inc.•September 9, 2011

Acorda Therapeutics Inc. – FDA Warning Letter, Sep 9, 2011

Record Details

On May 10, 2012, the FDA issued a Warning Letter to Acorda Therapeutics Inc. following an inspection from August 15 to September 9, 2011. The inspection identified significant violations of Section 505(k) of the Federal Food, Drug, and Cosmetic Act and 21 CFR §§ 314.80 and 314.81, concerning postmarketing adverse drug experience (ADE) reporting.

Repeat violations from previous inspections in 2006 and 2009 were noted, including late submission of 15-day Alert reports and failure to develop written procedures. Specific violations from the 2011 inspection included:

1. **Failure to submit serious and unexpected ADEs within 15 calendar days:** Approximately (b)(4) late ADE reports were submitted between January 22, 2010, and August 15, 2011, including deaths, irregular heartbeats, and acute fulminant hepatitis. Some reports were over 100 days late. Corrective actions, such as changing contractors, were ineffective, as (b)(4) late reports occurred after implementation. 2. **Failure to develop adequate written procedures for ADE surveillance, receipt, evaluation, and reporting:** The firm lacked procedures to ensure ADEs were detected, identified, assessed, and reported, contributing to untimely reporting.

Company
Acorda Therapeutics Inc.
Inspection date
September 9, 2011
Product type
Drugs
Office
Department of Health and Human Services
Person
  • Ronald M. Pace (Program Director)
View Company Profile

ID · b5a92885-4f33-41c5-a019-bf7922484914

Violation Codes10
21 U.S.C. 355(k)21 CFR 314.8021 U.S.C. 355(k)(1)21 CFR 314.8121 U.S.C. 331(e)21 CFR 314.80(c)(1)(i)21 CFR 314.80(b)21 CFR 314.80(c)(1)(ii)21 CFR 314.80(i)21 CFR 314.80(c)(2)(i)

Full citation text and observation details available on the Dashboard.

Other documents for Acorda Therapeutics Inc.
  • CRL

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Acorda Therapeutics Inc.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.